

David B Sykes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7079415/publications.pdf>

Version: 2024-02-01

82
papers

2,956
citations

257450

24
h-index

189892

50
g-index

89
all docs

89
docs citations

89
times ranked

5082
citing authors

#	ARTICLE	IF	CITATIONS
1	KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs. <i>Cancer Discovery</i> , 2022, 12, 792-811.	9.4	33
2	A new murine model of Barth syndrome neutropenia links TFAZZIN deficiency to increased ER stress-induced apoptosis. <i>Blood Advances</i> , 2022, 6, 2557-2577.	5.2	10
3	JAK inhibition in a patient with a STAT1 gain-of-function variant reveals STAT1 dysregulation as a common feature of aplastic anemia. <i>Med</i> , 2022, 3, 42-57.e5.	4.4	11
4	TREM2 is required for enhanced OpZ-induced superoxide generation following priming. <i>Journal of Leukocyte Biology</i> , 2022, , .	3.3	1
5	TLR Signaling Rescues Fungicidal Activity in Syk-Deficient Neutrophils. <i>Journal of Immunology</i> , 2022, 208, 1664-1674.	0.8	3
6	Transfusable neutrophil progenitors as cellular therapy for the prevention of invasive fungal infections. <i>Journal of Leukocyte Biology</i> , 2022, 111, 1133-1145.	3.3	6
7	Disruption of dNTP homeostasis by ribonucleotide reductase hyperactivation overcomes AML differentiation blockade. <i>Blood</i> , 2022, 139, 3752-3770.	1.4	12
8	Regulation of chromatin accessibility by the histone chaperone CAF-1 sustains lineage fidelity. <i>Nature Communications</i> , 2022, 13, 2350.	12.8	8
9	Spatiotemporal multiplexed immunofluorescence imaging of living cells and tissues with bioorthogonal cycling of fluorescent probes. <i>Nature Biotechnology</i> , 2022, 40, 1654-1662.	17.5	42
10	Abstract 982: A new transcriptional metastatic signature predicts survival in clear cell renal cell carcinoma. <i>Cancer Research</i> , 2022, 82, 982-982.	0.9	0
11	In vivo genome-wide CRISPR screening in murine acute myeloid leukemia uncovers microenvironmental dependencies. <i>Blood Advances</i> , 2022, 6, 5072-5084.	5.2	6
12	A case of antisyndetase syndrome with thrombotic thrombocytopenic purpura. <i>Rheumatology</i> , 2021, 60, e143-e145.	1.9	2
13	Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia. <i>IScience</i> , 2021, 24, 102651.	4.1	4
14	Severe babesiosis with associated splenic infarcts and asplenia. <i>Baylor University Medical Center Proceedings</i> , 2021, 34, 597-599.	0.5	1
15	A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. <i>Clinical Cancer Research</i> , 2021, 27, 4836-4847.	7.0	20
16	Host defense against fungal pathogens: Adaptable neutrophil responses and the promise of therapeutic opportunities?. <i>PLoS Pathogens</i> , 2021, 17, e1009691.	4.7	4
17	Neutrophils require SKAP2 for reactive oxygen species production following C-type lectin and <i>Candida</i> stimulation. <i>IScience</i> , 2021, 24, 102871.	4.1	7
18	Severe autoimmune hemolytic anemia following receipt of <sc>SARSâ€CoV</sc>â€2 <sc>mRNA</sc> vaccine. <i>Transfusion</i> , 2021, 61, 3267-3271.	1.6	29

#	ARTICLE	IF	CITATIONS
19	Systematic tissue collection during clinical breast biopsy is feasible, safe and enables high-content translational analyses. <i>Npj Precision Oncology</i> , 2021, 5, 85.	5.4	1
20	tiRNA signaling via stress-regulated vesicle transfer in the hematopoietic niche. <i>Cell Stem Cell</i> , 2021, 28, 2090-2103.e9.	11.1	20
21	Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment. <i>Cancer Cell</i> , 2021, 39, 1464-1478.e8.	16.8	98
22	Chromatin-state barriers enforce an irreversible mammalian cell fate decision. <i>Cell Reports</i> , 2021, 37, 109967.	6.4	28
23	Induction of a Timed Metabolic Collapse to Overcome Cancer Chemoresistance. <i>Cell Metabolism</i> , 2020, 32, 391-403.e6.	16.2	79
24	The Art of Oncology: COVID-19 Era. <i>Oncologist</i> , 2020, 25, 997-1000.	3.7	6
25	Spleen Tyrosine Kinase Is a Critical Regulator of Neutrophil Responses to <i>Candida</i> Species. <i>MBio</i> , 2020, 11, .	4.1	25
26	Aldehyde dehydrogenase 3a2 protects AML cells from oxidative death and the synthetic lethality of ferroptosis inducers. <i>Blood</i> , 2020, 136, 1303-1316.	1.4	68
27	SKAP2 is required for defense against <i>K. pneumoniae</i> infection and neutrophil respiratory burst. <i>ELife</i> , 2020, 9, .	6.0	18
28	Chromatin accessibility promotes hematopoietic and leukemia stem cell activity. <i>Nature Communications</i> , 2020, 11, 1406.	12.8	32
29	Case 10-2020: An 83-Year-Old Man with Pancytopenia and Acute Renal Failure. <i>New England Journal of Medicine</i> , 2020, 382, 1258-1266.	27.0	4
30	A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia. <i>Blood Advances</i> , 2020, 4, 445-448.	5.2	11
31	The TEMPI syndrome. <i>Blood</i> , 2020, 135, 1199-1203.	1.4	30
32	A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. <i>Blood Advances</i> , 2020, 4, 9-18.	5.2	56
33	Glycerol-3-phosphate is an FGF23 regulator derived from the injured kidney. <i>Journal of Clinical Investigation</i> , 2020, 130, 1513-1526.	8.2	75
34	A man with polycythemia vera, myelodysplastic syndrome and acquired microcytosis. <i>BMJ Case Reports</i> , 2019, 12, e229695.	0.5	0
35	Insights From a Patient With Lung Cancerâ€”Party Therapy Is Way Better Than Chemotherapy. <i>JAMA Oncology</i> , 2019, 5, 1685.	7.1	0
36	Frontline Science: Employing enzymatic treatment options for management of ocular biofilm-based infections. <i>Journal of Leukocyte Biology</i> , 2019, 105, 1099-1110.	3.3	20

#	ARTICLE	IF	CITATIONS
37	The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies. <i>Leukemia</i> , 2019, 33, 2403-2415.	7.2	138
38	Immune neutropenia mediated by micafungin. <i>American Journal of Hematology</i> , 2019, 94, 830-832.	4.1	3
39	Loss of FLT3 Sensitizes Myeloid Cells to Differentiation Via DHODH Inhibition. <i>Blood</i> , 2019, 134, 2712-2712.	1.4	2
40	Functionally Distinct Subsets of Monocytes in Mouse and Human Blood. <i>Blood</i> , 2019, 134, 438-438.	1.4	0
41	Niche Transfer of Small Non-Coding RNAs Regulates Hematopoietic Response to Stress. <i>Blood</i> , 2019, 134, 1207-1207.	1.4	0
42	What Links Neutropenia to Immature Cardiolipin in Patients with Barth Syndrome (tafazzin-deficiency)?. <i>Blood</i> , 2019, 134, 3579-3579.	1.4	0
43	The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 893-898.	3.4	77
44	Biguanides enhance antifungal activity against <i>Candida glabrata</i> . <i>Virulence</i> , 2018, 9, 1150-1162.	4.4	15
45	An unappreciated role for neutrophil-DC hybrids in immunity to invasive fungal infections. <i>PLoS Pathogens</i> , 2018, 14, e1007073.	4.7	49
46	Fluorescent Tracking of Yeast Division Clarifies the Essential Role of Spleen Tyrosine Kinase in the Intracellular Control of <i>Candida glabrata</i> in Macrophages. <i>Frontiers in Immunology</i> , 2018, 9, 1058.	4.8	17
47	Complete Responses in the TEMPI Syndrome after Treatment with Daratumumab. <i>New England Journal of Medicine</i> , 2018, 378, 2240-2242.	27.0	26
48	Modulating Cell Fate as a Therapeutic Strategy. <i>Cell Stem Cell</i> , 2018, 23, 329-341.	11.1	40
49	DHODH Inhibitors in the Treatment of Acute Myeloid Leukemia: Defining the Mechanism of Action and the Basis of the Metabolic Therapeutic Window. <i>Blood</i> , 2018, 132, 2716-2716.	1.4	2
50	Specific Bone Marrow Mesenchymal Subsets in Patients with Myelodysplastic Syndromes Harbor Molecular Perturbations That Alter the Dynamics of Competition between Pre-Leukemic Clones and Normal Cells. <i>Blood</i> , 2018, 132, 938-938.	1.4	0
51	The metabolic regulator mTORC1 controls terminal myeloid differentiation. <i>Science Immunology</i> , 2017, 2, .	11.9	23
52	Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease. <i>Nature Medicine</i> , 2017, 23, 100-106.	30.7	121
53	Case 40-2017. <i>New England Journal of Medicine</i> , 2017, 377, 2581-2590.	27.0	2
54	Acquired haemophilia A with a recalcitrant high-titre factor VIII inhibitor in the setting of interstitial lung disease. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-220932.	0.5	2

#	ARTICLE	IF	CITATIONS
55	Osteoblastic Cell-Derived Extracellular Vesicles Transfer Small RNAs That Alter the Physiology of Hematopoietic Cells <i>in Vivo</i> . <i>Blood</i> , 2017, 130, 93-93.	1.4	0
56	Development of ML390: A Human DHODH Inhibitor That Induces Differentiation in Acute Myeloid Leukemia. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 1112-1117.	2.8	51
57	Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia. <i>Cell</i> , 2016, 167, 171-186.e15.	28.9	353
58	Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin. <i>Nature Biotechnology</i> , 2016, 34, 738-745.	17.5	176
59	Single Targeted Exon Mutation Creates a True Congenic Mouse for Competitive Hematopoietic Stem Cell Transplantation: The C57BL/6-CD45.1STEM Mouse. <i>Stem Cell Reports</i> , 2016, 6, 985-992.	4.8	54
60	Inhibition of the Enzyme Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1656-1656.	1.4	3
61	RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability. <i>Cell Reports</i> , 2015, 13, 2345-2352.	6.4	28
62	Difficulties in hematopoietic progenitor cell collection from a patient with TEMPI syndrome and severe iatrogenic iron deficiency. <i>Transfusion</i> , 2015, 55, 2142-2148.	1.6	10
63	Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors. <i>Cell Reports</i> , 2015, 10, 755-770.	6.4	21
64	Hormones and the Bone Marrow: Panhypopituitarism and Pancytopenia in a Man with a Pituitary Adenoma. <i>Journal of General Internal Medicine</i> , 2015, 30, 692-696.	2.6	10
65	Bone marrow findings of the newly described TEMPI syndrome: when erythrocytosis and plasma cell dyscrasia coexist. <i>Modern Pathology</i> , 2015, 28, 367-372.	5.5	30
66	Immunotoxin Enables Non-Genotoxic Conditioning for Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 32-32.	1.4	1
67	Neutrophils Derived from Ezh2 ^{-/-} Progenitor Cells Demonstrate Aberrant Erythroid Lineage Gene Expression. <i>Blood</i> , 2015, 126, 4112-4112.	1.4	0
68	Case report: a 37-year-old male with telangiectasias, polycythemia vera, perinephric fluid collections, and intrapulmonary shunting. <i>BMC Hematology</i> , 2014, 14, 11.	2.6	5
69	Dectin-1 Activation Controls Maturation of β -1,3-Glucan-containing Phagosomes. <i>Journal of Biological Chemistry</i> , 2013, 288, 16043-16054.	3.4	80
70	SIRT1 regulates differentiation of mesenchymal stem cells by deacetylating β -catenin. <i>EMBO Molecular Medicine</i> , 2013, 5, 430-440.	6.9	233
71	Functional Defects In Neutrophils Derived From Ezh2 Null Mice. <i>Blood</i> , 2013, 122, 1556-1556.	1.4	5
72	Targeting Pre-B Cell Receptor and BCL6 In TCF3-PBX1 B-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 349-349.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Complete and Partial Responses of the TEMPI Syndrome to Bortezomib. <i>New England Journal of Medicine</i> , 2012, 367, 778-780.	27.0	32
74	Niche-Based Screening Identifies Novel Small Molecules That Overcome Stromal Effects in Multiple Myeloma. <i>Blood</i> , 2012, 120, 571-571.	1.4	1
75	Identifying Small Molecules That Overcome HoxA9-Mediated Differentiation Arrest in Acute Myeloid Leukemia. <i>Blood</i> , 2012, 120, 3513-3513.	1.4	0
76	TEMPI: A Reversible Syndrome Following Treatment with Bortezomib. <i>Blood</i> , 2012, 120, 986-986.	1.4	1
77	Aldehyde Dehydrogenase 3a2 (Aldh3a2) Represents a Distinct Metabolic Vulnerability in MLL-AF9 AML Leukemia Initiating Cells. <i>Blood</i> , 2012, 120, 208-208.	1.4	0
78	The TEMPI Syndrome – A Novel Multisystem Disease. <i>New England Journal of Medicine</i> , 2011, 365, 475-477.	27.0	77
79	The TEMPI Syndrome: Telangiectasias, Elevated Erythropoietin and Erythrocytosis, Monoclonal Gammopathy, Perinephric Fluid Collections, and Intrapulmonary Shunting. <i>Blood</i> , 2011, 118, 1037-1037.	1.4	0
80	Quantitative production of macrophages or neutrophils ex vivo using conditional Hoxb8. <i>Nature Methods</i> , 2006, 3, 287-293.	19.0	337
81	Estrogen-dependent E2a/Pbx1 myeloid cell lines exhibit conditional differentiation that can be arrested by other leukemic oncoproteins. <i>Blood</i> , 2001, 98, 2308-2318.	1.4	35
82	Hoxa9 Immortalizes a Granulocyte-Macrophage Colony-Stimulating Factor-Dependent Promyelocyte Capable of Biphenotypic Differentiation to Neutrophils or Macrophages, Independent of Enforced Meis Expression. <i>Molecular and Cellular Biology</i> , 2000, 20, 3274-3285.	2.3	122